Table 1.
Baseline clinical characteristics of all type 1 diabetes patients
| Characteristics | Overall (n = 11,475) | SGLT2i(+) (n = 1,898) | SGLT2i(−) (n = 9,577) | P‐value [SGLT2i(+) vs SGLT2i(−)] |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 5,469 (47.7) | 900 (47.4) | 4,569 (47.7) | 0.976 |
| Female | 6,006 (52.3) | 998 (52.6) | 5,008 (52.3) | |
| Age | ||||
| Mean (years) | 53.6 ± 19.3 | 55.8 ± 15.0 | 53.3 ± 2.0 | 0.003 |
| Distribution, n (%) | ||||
| <25 | 1,009 (8.8) | 54 (2.8) | 955 (10.0) | <0.001 |
| 25–44 | 2,480 (21.6) | 439 (23.1) | 2,041 (21.3) | |
| 45–64 | 4,144 (36.1) | 848 (44.7) | 3,296 (34.4) | |
| ≥65 | 3,842 (33.5) | 557 (29.3) | 3,285 (34.3) | |
| BMI | ||||
| Mean (kg/m2) | 22.3 ± 5.0 | 24.5 ± 4.9 | 21.8 ± 4.8 | 0.211 |
| Distribution, n (%) | ||||
| <25 | 8,750 (76.3) | 1,093 (57.6) | 7,657 (80.0) | <0.001 |
| ≥25 | 2725 (23.7) | 805 (42.4) | 1,920 (20.0) | |
| Insulin regimen, n (%) | ||||
| MDI | 10,600 (92.4) | 1,767 (93.1) | 8,833 (92.2) | 0.194 |
| CSII | 875 (7.6) | 131 (6.9) | 744 (7.8) | |
Data shown as mean ± standard deviation. Body mass index (BMI) is weight in kilograms divided by the square of height in meters.
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection; SGLT2i(+), patients treated with sodium–glucose cotransporter 2 inhibitors; SGLT2i(−), patients treated without sodium–glucose cotransporter 2 inhibitors.